


Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round

Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease

Augustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the Clinic

Saniona’s Joint Venture, Cephagenix, Secures Seed Funding from AdBio Partners and AbbVie Ventures
